During T Cell Activation a TNF-Apoptosis-Inducing Ligand (TRAIL), and B Ligand (RANKL), TNF-Related k Factor-CD95 Ligand, Receptor Activator of Nuclear Differential Regulation of the Expression of

Members of TNF superfamily are characterized by their ability to inflict apoptosis upon binding to their cognate receptors in a homotrimeric manner. These proteins are expressed on different cell types under various conditions. However, the mechanisms governing the expression of these molecules remain elusive. We have found that the TCR signal can elicit the expression of receptor activator of NF- k B ligand (RANKL), TNF- a , CD95L, and TNF-related apoptosis inducing ligand (TRAIL) in T cell hybridoma A1.1 cells, thus allowing us to examine the expression pattern of these molecules under precisely the same conditions. We have previously reported that CD95L expression requires both protein kinase C (PKC) translocation and Ca 2 1 mobilization and is inhibited by cyclosporin A, and dexamethasone. We demonstrate now that activation-induced expression of RANKL is mediated by Ca 2 1 mobilization. PKC activation does not induce RANKL expression nor does it synergize with the Ca 2 1 signal. Activation-induced RANKL expression is blocked by cyclosporin A, but not by dexamethasone. The expression of TNF, in contrast, is mediated by PKC, but not by Ca 2 1 . TNF- a expression is not inhibited by cyclosporin A, but is sensitive to dexamethasone. A1.1 cells constitutively express TRAIL at low levels. Stimulation with anti-CD3 leads to an initial reduction and subsequent increase in TRAIL expression. TRAIL induction is not inhibited by cyclosporin A, but highly sensitive to dexamethasone. Therefore, expression of the TNF superfamily genes is regulated by distinct signals. Detailed understanding of the regulatory mechanisms could provide crucial information concerning the role of these molecules in the modulation of the

[1]  Emad S. Alnemri,et al.  Temperature-sensitive Differential Affinity of TRAIL for Its Receptors , 2000, The Journal of Biological Chemistry.

[2]  M. Weller,et al.  Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells , 2000, Cell Death and Differentiation.

[3]  R. Natarajan,et al.  Molecular Mechanisms of Tumor Necrosis Factor α Gene Expression in Monocytic Cells via Hyperglycemia-induced Oxidant Stress-dependent and -independent Pathways* , 2000, The Journal of Biological Chemistry.

[4]  YOUHAI H. Chen,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression , 2000, The Journal of experimental medicine.

[5]  D. Green,et al.  Protein kinase ctheta cooperates with calcineurin to induce Fas ligand expression during activation-induced T cell death. , 1999, Journal of immunology.

[6]  Hsiu-Hsiang Lee,et al.  NF‐κB‐dependent Fas ligand expression , 1999 .

[7]  J. Peschon,et al.  IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. , 1999, Journal of immunology.

[8]  L. Samelson,et al.  T cell antigen-receptor signal transduction. , 1999, Current opinion in immunology.

[9]  Yongwon Choi,et al.  TRANCE is a TNF family member that regulates dendritic cell and osteoclast function , 1999, Journal of leukocyte biology.

[10]  K. Okumura,et al.  Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs , 1999, The Journal of experimental medicine.

[11]  M. Degli-Esposti To die or not to die—the quest of the TRAIL receptors , 1999, Journal of leukocyte biology.

[12]  L. D’Adamio,et al.  Regulation of Fas ligand expression and cell death by apoptosis-linked gene 4 , 1999, Nature Medicine.

[13]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[14]  J. Penninger,et al.  Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development , 1999, Immunology and cell biology.

[15]  N. Udagawa,et al.  A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. , 1999, Biochemical and biophysical research communications.

[16]  J. Lord,et al.  Regulation of cell surface expression of Fas (CD95) ligand and susceptibility to Fas (CD95)‐mediated apoptosis in activation‐induced T cell death involves calcineurin and protein kinase C, respectively , 1999, European journal of immunology.

[17]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[18]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[19]  E. Reddy,et al.  Modulation of life and death by the TNF receptor superfamily , 1998, Oncogene.

[20]  E. Alnemri,et al.  Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells , 1998, The Journal of experimental medicine.

[21]  J. Borst,et al.  Tumor necrosis factor receptor family members in the immune system. , 1998, Seminars in immunology.

[22]  M. Bevan,et al.  RORgamma t, a novel isoform of an orphan receptor, negatively regulates Fas ligand expression and IL-2 production in T cells. , 1998, Immunity.

[23]  L. Hood,et al.  OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. , 1998, Journal of immunology.

[24]  S. Ju,et al.  Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma. , 1998, Journal of immunology.

[25]  Yufang Shi,et al.  Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression , 1998, Oncogene.

[26]  L. Zhang,et al.  Protein kinase C regulates Fas (CD95/APO-1) expression. , 1998, Journal of immunology.

[27]  M. Chao,et al.  TNF-related ligands and their receptors. , 1998, Cellular signalling.

[28]  J. Ashwell,et al.  Cyclosporin A-Sensitive Transcription Factor Egr-3 Regulates Fas Ligand Expression , 1998, Molecular and Cellular Biology.

[29]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Mochizuki,et al.  Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.

[31]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[32]  Andrew D. Badley,et al.  Transcriptional Regulation of the Human FasL Promoter-Enhancer Region* , 1998, The Journal of Biological Chemistry.

[33]  S. Nagata Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model , 1998, Journal of Human Genetics.

[34]  S. Eliason,et al.  Two NFAT Transcription Factor Binding Sites Participate in the Regulation of CD95 (Fas) Ligand Expression in Activated Human T Cells* , 1997, The Journal of Biological Chemistry.

[35]  C. Kirk,et al.  Early activation defects in T lymphocytes from aged mice , 1997, Immunological reviews.

[36]  P. Golstein Cell death: TRAIL and its receptors. , 1997, Current biology : CB.

[37]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[38]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[39]  S. Eliason,et al.  Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. , 1997, Journal of immunology.

[40]  A. Asada,et al.  Regulation of T Cell Apoptosis via T Cell Receptors and Steroid Receptors , 1996, Stem cells.

[41]  D. Thanos,et al.  Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN , 1996, Molecular and cellular biology.

[42]  J. Ashwell,et al.  Cross‐Talk between the T Cell Antigen Receptor and the Glucocorticoid Receptor Regulates Thymocyte Development , 1996, Stem cells.

[43]  Surendra Sharma,et al.  Characterization of a New Isoform of the NFAT (Nuclear Factor of Activated T Cells) Gene Family Member NFATc* , 1996, The Journal of Biological Chemistry.

[44]  D. Green,et al.  Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. , 1996, International immunology.

[45]  S. Ju,et al.  Regulation of T-cell death genes: selective inhibition of FasL- but not Fas-mediated function. , 1996, Cellular immunology.

[46]  D. Margulies,et al.  A targeted glucocorticoid receptor antisense transgene increases thymocyte apoptosis and alters thymocyte development. , 1995, Immunity.

[47]  A. Israël,et al.  Activation of NF-κB by the Tax Protein of HTLV-1 , 1995 .

[48]  C. Ware,et al.  Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids , 1995, The Journal of experimental medicine.

[49]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[50]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[51]  Stuart L. Schrieber,et al.  Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells , 1994, The Journal of experimental medicine.

[52]  J. Ashwell,et al.  To be or not to be: mutually antagonistic death signals regulate thymocyte apoptosis. , 1994, International archives of allergy and immunology.

[53]  Dan R. Littman,et al.  Signal transduction by lymphocyte antigen receptors , 1994, Cell.

[54]  F. Paliogianni,et al.  Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor. , 1993, Journal of immunology.

[55]  J. Strominger,et al.  Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor alpha gene promoter , 1993, The Journal of experimental medicine.

[56]  J. Bach,et al.  Immunosuppressive therapy of autoimmune diseases. , 1993, Trends in pharmacological sciences.

[57]  J. Economou,et al.  The regulation of the human tumor necrosis factor alpha promoter region in macrophage, T cell, and B cell lines. , 1992, The Journal of biological chemistry.

[58]  M. Vincenti,et al.  Regulation of NF‐κB activity in murine macrophages: Effect of bacterial lipopolysaccharide and phorbol ester , 1992 .

[59]  M. Iwata,et al.  Regulation of T lymphocyte apoptosis. Signals for the antagonism between activation- and glucocorticoid-induced death. , 1991, Journal of immunology.

[60]  J. Strominger,et al.  Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines , 1991, The Journal of experimental medicine.

[61]  M. Merćep,et al.  Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. , 1990, Journal of immunology.

[62]  D. Green,et al.  Activation-induced cell death in T cell hybridomas is due to apoptosis. Morphologic aspects and DNA fragmentation. , 1990, Journal of immunology.

[63]  Beni M. Sahai,et al.  Cyclosporin A inhibits activation-induced cell death in T-cell hybridomas and thymocytes , 1989, Nature.

[64]  M. Merćep,et al.  The cell cycle block and lysis of an activated T cell hybridoma are distinct processes with different Ca2+ requirements and sensitivity to cyclosporine A. , 1989, Journal of immunology.

[65]  R. Busse,et al.  Differential role of extra‐ and intracellular calcium in the release of EDRF and prostacyclin from cultured endothelial cells , 1988, British journal of pharmacology.

[66]  J. Bluestone,et al.  Inhibition of transformed T cell growth in vitro by monoclonal antibodies directed against distinct activating molecules. , 1988, Journal of immunology.

[67]  A. Fotedar,et al.  Fine specificity of antigen recognition by T cell hybridoma clones specific for poly-18: a synthetic polypeptide antigen of defined sequence and conformation. , 1985, Journal of immunology.

[68]  A. Rao,et al.  Role of the cyclosporin-sensitive transcription factor NFAT1 in the allergic response. , 1997, Memorias do Instituto Oswaldo Cruz.

[69]  H. Gruss,et al.  Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily , 1996, International journal of clinical & laboratory research.

[70]  S. Nagata A death factor--the other side of the coin. , 1996, Behring Institute Mitteilungen.

[71]  D. Cosman A family of ligands for the TNF receptor superfamily , 1994, Stem cells.

[72]  B. Bierer Biology of cyclosporin A and FK506. , 1994, Progress in clinical and biological research.